Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Testing Cooperative's Hematologic Neoplasms, Solid Tumor Tests Receive NY State Approval, Medicare Coverage

NEW YORK – Genomic Testing Cooperative announced on Wednesday that the New York State Clinical Evaluation Program has approved its next-generation sequencing profiling tests for hematologic neoplasms and solid tumors.

The approved tests are the GTC Hematology Profile for 177 genes; GTC Hematology Fusion/Expression for 1,408 genes; GTC Hematology PLUS for 177 DNA and 1,408 RNA; GTC Liquid Biopsy, Hematology Profile for 177 genes; GTC Solid Tumor Profile for 434 genes; GTC Solid Tumor Profile Fusion/Expression for 1,408 genes; and GTC Solid Tumor PLUS for 434 DNA and 1,408 RNA.

The tests are also covered by Medicare Administrative Contractor Palmetto GBA, Irvine, California-based GTC said in a statement, adding they are designed to comprehensively evaluate "clinically relevant molecular abnormalities and biomarkers." The tests can be performed on small samples, including needle aspiration samples, and rely on artificial intelligence to analyze sequencing runs, curate data, and interpret results.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.